Ascend Laboratories Competitors and Similar CompaniesClear all

Ascend Laboratories's competitors and similar companies include Medochemie, Quantum Pharmaceutical, Zydus Lifesciences and Grupo Menarini.

	Ascend Laboratories Ascend Laboratories is a company developing pharmaceutical products.	Medochemie Medochemie is a pharmaceutical company.	Quantum Pharmaceutical Quantum Pharmaceutical is a manufacturer and supplier of unlicensed medicines and hard-to-source products.	Zydus Lifesciences Zydus Lifesciences (formerly known as Cadila Healthcare) is a company that provides healthcare solutions.	Grupo Menarini Grupo Menarini is a pharmaceutical company.
Founding Date	Founding Date 2000	Founding Date 1976	Founding Date 2004	Founding Date 1952	Founding Date 1961
Type	Type Private	Type Private	Type Subsidiary	Type Public	Type Private
Tags	Tags Healthcare distribution drug development pharma	Tags Healthcare distribution drug development pharma	Tags Healthcare distribution drug development pharma	Tags Healthcare distribution drug development pharma	Tags Healthcare distribution drug development pharma
Locations	Locations Parsippany-Troy Hills, US HQ Newington, US	Locations Λεμεσός, CY HQ Ben Aknoun, DZ Amman, JO Rīga, LV Chișinău, MD Moscow, RU	Locations Hobson, GB HQ	Locations Ahmedabad, IN HQ Rio De Janeiro, BR Nanterre, FR Ahmedabad, IN Ambernath, IN Ankleshwar, IN Bengaluru, IN see more	Locations Badalona, ES HQ
Employees	Employees 522% decrease	Employees 825	Employees 4548% increase	Employees 27,9176% increase	Employees 5541% increase
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) £76.1m (FY, 2018)	Revenue (est.) ₹267.2b (FY, 2026)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods £54.5m (FY, 2018)	Cost of goods ₹72.9b (FY, 2026)	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit £21.6m (FY, 2018)	Gross profit ₹203.7b (FY, 2026)	Gross profit N/A
Net income	Net income N/A	Net income N/A	Net income (£8.3m) (FY, 2018)	Net income ₹50.3b (FY, 2026)	Net income N/A